<DOC>
	<DOCNO>NCT00818961</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy donor stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving monoclonal antibody , alemtuzumab , transplant tacrolimus methotrexate transplant may stop happen . PURPOSE : This phase II trial study side effect donor stem cell transplant see well work treat patient high-risk hematologic cancer .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With High-Risk Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate safety toxicity reduced-intensity condition regimen follow allogeneic bone marrow peripheral blood stem cell transplantation HLA-matched unrelated donor patient high-risk hematologic malignancy . - To evaluate engraftment peripheral blood chimerism analysis . - To determine incidence severity acute chronic graft-versus-host disease follow transplant . - To examine possibility control hematologic malignancy induction graft-versus-leukemia/tumor effect . - To determine disease-free survival , relapse , transplant-related mortality , death cause . OUTLINE : - Reduced-intensity conditioning regimen : Patients receive 1 2 conditioning regimen accord diagnosis . - Regimen 1 ( acute leukemia , myelodysplastic syndrome , myeloproliferative syndrome , chronic myelogenous leukemia ) : Patients receive fludarabine phosphate IV 30 minute busulfan IV 3 hour day -6 -3 orally 4 time daily day -7 -3 . - Regimen 2 ( lymphoproliferative malignancy ) : Patients receive fludarabine phosphate IV 30 minute cyclophosphamide IV 1 hour day -5 -3 . Patients CD20+ malignancy also receive rituximab IV 4-6 hour day -13 , -6 , 1 , 8 . - Transplantation : Patients undergo allogeneic bone marrow peripheral blood stem cell transplantation day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive low-dose alemtuzumab subcutaneously day -11 -9 tacrolimus IV 24 hour begin day -3 orally twice daily begin day 14 continue day 60 , follow taper day 180 absence clinically significant GVHD . Patients also receive methotrexate day 1 , 3 , 6 . Patients exhibit persistent mixed chimerism disease relapse/progression despite full withdrawal immunosuppression may receive 3 donor lymphocyte infusion . Blood sample take day 30 , 60 , 100 every 4 week thereafter chimerism study PCR analysis . After completion study therapy , patient follow periodically 60 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Diagnosis one follow hematological malignancy : CML , 1 following : In first CP AND fail imatinib mesylate therapy , defined failure obtain hematologic remission 3 month major cytogenetic response ( i.e. , Ph+ cell &lt; 35 % ) 6 month demonstrate clonal evolution disease progression therapy In accelerated phase &lt; 15 % blast In blast crisis enter second CP follow induction chemotherapy AML , 1 following : In second subsequent complete remission ( CR ) ( i.e. , &lt; 5 % blast morphology , residual leukemia flow cytometry , absence cytogenetic abnormality ) Failed primary induction chemotherapy , subsequently enter CR ≤ 2 subsequent reinduction chemotherapy treatment ( ) In first CR intermediaterisk poorrisk cytogenetics ALL 1 follow : In second subsequent CR In first CR AND presence ( 9 ; 22 ) MDS , follow : Highrisk disease , define IPSS score ≥ 1.5 diagnosis AND meet 1 follow criterion : ≤ 10 % blast diagnosis In morphologic CR ( &lt; 5 % blast ) follow cytoreductive chemotherapy CMML , 1 following : ≤ 10 % blast diagnosis In morphologic CR ( &lt; 5 % blast ) follow cytoreductive chemotherapy CLL/PLL following : Rai stage IIV disease Failed ≥ 1 prior chemotherapy regimen ( include fludarabine phosphate ) ASCT Documented chemosensitive stable , nonbulky disease prior transplant , define &lt; 20 % bone marrow involvement AND lymph node size &lt; 3 cm axial diameter No bulky tumor mass , elevate lactate dehydrogenase ( LDH ) , B symptom , progressive disease prior transplant Lowgrade nonHodgkin lymphoma ( NHL ) ( i.e. , small lymphocytic lymphoma , follicular center lymphoma [ grade 1 2 ] , marginal zone lymphoma , Bcell lymphoma ) , follow criterion : Failed ≥ 1 prior chemotherapy regimen ASCT Documented chemosensitive stable , nonbulky disease prior transplant , define &lt; 20 % bone marrow involvement AND lymph node size &lt; 3 cm axial diameter Received ≤ 3 prior chemotherapy regimen ( monoclonal antibody therapy involvedfield radiotherapy consider prior regimen ) No bulky tumor mass , elevate LDH , B symptom , progressive disease prior transplant Mantle cell lymphoma , follow : Failed achieve remission recur either conventional chemotherapy ASCT Responsive stable disease recent prior therapy No bulky tumor mass , elevate LDH , B symptom , progressive disease prior transplant Intermediategrade NHL ( i.e. , follicular center lymphoma [ grade 3 ] diffuse large cell lymphoma ) , meet follow criterion : Failed achieve remission recur either conventional chemotherapy ASCT Documented chemosensitive , nonbulky disease prior transplant , define least partial remission salvage chemotherapy ( ≥ 50 % reduction diameter disease site ) No bulky tumor mass , elevate LDH , B symptom , progressive disease prior transplant Hodgkin lymphoma , follow : Relapsed prior ASCT OR ≥ 2 combination chemotherapy regimens ineligible ASCT Documented chemosensitive , nonbulky disease prior transplant , define least partial remission salvage chemotherapy ( ≥ 50 % reduction diameter disease site ) No bulky tumor mass , elevate LDH , B symptom , progressive disease prior transplant Peripheral Tcell NHL , follow : Failed achieve remission recur either conventional chemotherapy ASCT Documented chemosensitive , nonbulky disease prior transplant , define least partial remission salvage chemotherapy ( ≥ 50 % reduction diameter disease site ) No bulky tumor mass , elevate LDH , B symptom , progressive disease prior transplant Myeloproliferative syndrome poor risk feature , meet 1 follow criterion : &lt; 55 year old AND Lille score 1 Lille score 2 HgB &lt; 10 g/dL AND abnormal karyotype Highrisk disease , 1 following : Age 4072 year Any age AND deem significantly increase risk morbidity death follow standard , myeloablative unrelated donor stem cell transplant ( e.g. , receive extensive prior therapy , include ASCT ) HLAmatched unrelated donor available , 1 following : 8/8 match HLAA , B , C , DR loci highresolution genotyping Single allelic mismatch either HLAB HLAC loci donor highresolution molecular type No single allelic mismatch HLAA HLADR loci KPS 80100 % Adapted weight Charlson Comorbidity Index &lt; 3 Serum creatinine ≤ 2.0 mg/dL AST ALT &lt; 3 time upper limit normal ( ULN ) Total bilirubin &lt; 1.5 time ULN LVEF ≥ 45 % DLCO &gt; 50 % No hypoxia rest oxygen saturation &lt; 92 % room air ( correct bronchodilator therapy ) No severe pulmonary function abnormalities No HIV infection No active hepatitis B C infection , opinion gastroenterologist transplant committee , place patient moderate high risk develop severe hepatic disease No active opportunistic infection ( e.g. , fungal pneumonia , tuberculosis , viral infection )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult AML 11q23 ( MLL ) abnormality</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell NHL</keyword>
	<keyword>stage I cutaneous T-cell NHL</keyword>
	<keyword>stage II cutaneous T-cell NHL</keyword>
	<keyword>stage III cutaneous T-cell NHL</keyword>
	<keyword>stage IV cutaneous T-cell NHL</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosal tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>contiguous st II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous st II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous st II adult diffuse sm cleave cell lymphoma</keyword>
	<keyword>contiguous st II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous st II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous st II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous st II mantle cell lymphoma</keyword>
	<keyword>contiguous st II marginal zone lymphoma</keyword>
	<keyword>contiguous st II small lymphocytic lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous st II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous st II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous st II adult diffuse sm cleave cell lymphoma</keyword>
	<keyword>noncontiguous st II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous st II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous st II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous st II mantle cell lymphoma</keyword>
	<keyword>noncontiguous st II marginal zone lymphoma</keyword>
	<keyword>noncontiguous st II small lymphocytic lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult gr III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>de novo MDS</keyword>
	<keyword>previously treat MDS</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease</keyword>
</DOC>